



# Invitation

## Guest Lecture

### Novel TB vaccines - will we finally control the epidemic?

Mathematical modelling suggests that control of the TB epidemic is not possible without a new vaccine that effectively prevents TB disease in adolescents and adults. The prospects for successful future vaccination against TB, and how to achieve this, will be discussed. M72/AS01E is a promising novel TB vaccine that has demonstrated 50% efficacy in preventing TB disease in adults in a phase 2b study. This vaccine is now in a phase 3 trial to assess efficacy definitively; however, contingency approaches are also needed: the clinical pipeline of novel TB vaccines remains sparsely populated.

Monday, 12 May 2025

Time: 14h00 - 15h30

Venue: SPH Resource centre, Public Health Building,  
Education Campus, Parktown

[RSVP HERE](#)

Speaker:

[Professor Willem Hanekom](#)



Willem Hanekom is executive director of the Africa Health Research Institute (AHRI, [www.ahri.org](http://www.ahri.org)) in KZN. This 830-person independent academic research institute has a vision of Optimal Health and Wellbeing of Under-resourced Populations. Willem holds a professor position at University College London and affiliate professor positions at the Universities of KZN, Cape Town and Washington. He has worked in TB vaccine discovery and development for most of his career, including directing the South African TB Vaccine Initiative (SATVI) at the UCT and the TB vaccine programme at the Gates Foundation. Willem is currently a strategic advisor to the WHO Director of Science on the WHO TB Vaccine Accelerator and serves on various global vaccination related advisory committees.